IMMUNOe International Research Centers

Centennial, Colorado 80112

0 studies enrolling now · 17 studies all time

What they study most

Alzheimer's Disease, Asperger's Disorder, Asthma, Atopic Dermatitis, Autism, Autistic Disorder, COPD, Chronic Obstructive Pulmonary Disease, Common Variable Immunodeficiency, Hereditary Angioedema, Hyper-IgM Syndrome, Migraine

Studies at this site

• HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) — Running, not enrolling
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 — Stopped early
• A Study of ARRY-502 in Patients With Persistent Asthma — Completed
• A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) — Completed
• Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis — Completed
• Phase 2/3 Study of IGSC, 20% in PIDD — Completed
• Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis — Stopped early
• Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study — Completed
• Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA) — Completed
• Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4) — Completed
• A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair) — Completed
• Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases — Completed
• An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum — Status unconfirmed
• Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency — Completed
• A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma — Completed
• A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR). — Completed